Loading data for GOSS — first visit, this takes a few seconds.
Gossamer Bio, Inc.
10.53 -0.20 (-1.86%)
10.91 +1.96%
- Market Cap
- $65.38M
- Volume
- 259K
- Dividend yield
- n/a
- Next earnings date
- Nov 4, 2026
Gossamer Bio, Inc. (GOSS) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $9.24M | n/a | -19.59% |
| EPS | -$8,17 | +$1,82 | +39.93% |
Metrics
- Bid
- 10.69
- Market Cap
- 65.4M
- Revenue (ttm)
- 53.3M
- Net Income (ttm)
- -125M
- 2.00
- -52.8
- n/a
- -0.69
- P/B (ttm)
- -55.73
- P/S (ttm)
- 1.23
- Earnings Date
- Nov 4, 2026
- Ask
- 10.67
- Volume
- 258,961
- Avg. Volume (20D)
- 346,484
- Open
- 10.95
- Previous Close
- 10.73
- Day's Range
- 10.07 - 11.08
- 52-Week Range
- 9.12 - 309.60
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Gossamer Bio, Inc.
View profile →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2019
Employees 161
Stock Exchange NasdaqGS
Ticker Symbol GOSS
Website https://www.gossamerbio.com